NEW YORK (GenomeWeb News) – Illumina said in a filing with the US Securities and Exchange Commission this week that Paul Grint plans to retire from the firm's board of directors, effective as of the next Illumina stockholder meeting.

Grint has been a director since 2005. He currently is senior VP at Forest Research Institute, and he previously was CMO at Kalypsys. He also has served as an executive at Zephyr Sciences, Pfizer, IDEC Pharmaceuticals, and Schering-Plough.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.